Treatment for the endocrine resistant breast cancer: Current options and future perspectives

Chun-Yu Liu; Chia-Yun Wu; Karineh Petrossian; Tzu-Ting Huang; Ling-Ming Tseng; Shiuan Chen

doi:10.1016/j.jsbmb.2017.07.001

Treatment for the endocrine resistant breast cancer: Current options and future perspectives

J Steroid Biochem Mol Biol. 2017 Sep:172:166-175. doi: 10.1016/j.jsbmb.2017.07.001. Epub 2017 Jul 3.

Authors

Chun-Yu Liu¹, Chia-Yun Wu¹, Karineh Petrossian², Tzu-Ting Huang³, Ling-Ming Tseng⁴, Shiuan Chen⁵

Affiliations

¹ Division of Medical Oncology, Department of Oncology, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan.
² Department of Cancer Biology, Beckman Research Institute of the City of Hope, United States.
³ Division of Medical Oncology, Department of Oncology, Taiwan.
⁴ Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan.
⁵ Department of Cancer Biology, Beckman Research Institute of the City of Hope, United States. Electronic address: schen@coh.org.

PMID: 28684381
DOI: 10.1016/j.jsbmb.2017.07.001

Abstract

Endocrine resistance remains a challenge and an unmet need for managing hormone receptor-positive breast cancer. The mechanisms of endocrine resistance are multifaceted and are likely to evolve over time following various single or combination therapies. The purpose of this review article is to provide general understanding of molecular basis of endocrine resistance of breast cancer and to offer comprehensive review on current treatment options and potential new treatment strategies for endocrine resistant breast cancers. Last but not the least, we discuss current challenges and future directions for management of endocrine resistant breast cancers.

Keywords: Breast cancer; Endocrine resistance; Estrogen receptor; Hormone receptor.

Publication types

Review

MeSH terms

Aminopyridines / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Benzamides / therapeutic use
Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics
Breast Neoplasms / metabolism
Breast Neoplasms / pathology
Drug Resistance, Neoplasm / drug effects*
Drug Resistance, Neoplasm / genetics
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics
ErbB Receptors / metabolism
Estradiol / analogs & derivatives
Estradiol / therapeutic use
Everolimus / therapeutic use
Female
Fulvestrant
Gene Expression Regulation, Neoplastic*
Humans
Mitogen-Activated Protein Kinases / antagonists & inhibitors
Mitogen-Activated Protein Kinases / genetics
Mitogen-Activated Protein Kinases / metabolism
Molecular Targeted Therapy / methods
Molecular Targeted Therapy / trends*
Morpholines / therapeutic use
Piperazines / therapeutic use
Pyridines / therapeutic use
Receptor, ErbB-2 / antagonists & inhibitors
Receptor, ErbB-2 / genetics
Receptor, ErbB-2 / metabolism
Receptors, Estrogen / antagonists & inhibitors
Receptors, Estrogen / genetics
Receptors, Estrogen / metabolism
Signal Transduction

Substances

Aminopyridines
Benzamides
Morpholines
NVP-BKM120
Piperazines
Pyridines
Receptors, Estrogen
entinostat
Fulvestrant
Estradiol
Everolimus
EGFR protein, human
ERBB2 protein, human
ErbB Receptors
Receptor, ErbB-2
Mitogen-Activated Protein Kinases
palbociclib